PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast-logo

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Education Podcasts

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Location:

United States

Description:

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Language:

English


Episodes

Marcia S. Brose, MD, PhD - A Visual Exploration of New Opportunities in Thyroid Cancer: Targeting RET Alterations to Optimize Outcomes

1/15/2021
Go online to PeerView.com/KTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in managing patients with thyroid cancer discusses the scientific background and rationale for molecular testing and targeted treatment of RET fusion/mutation–positive thyroid cancers, new data on novel targeted approaches, the importance of multidisciplinary collaboration, and how to effectively communicate with patients to promote...

Duration:00:36:06

William K. Oh, MD - Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes

1/13/2021
Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight...

Duration:01:04:56

Sagar Lonial, MD, FACP / Praneetha Thulasi, MD - Targeting Ocular Toxicity in Multiple Myeloma: Opportunities for Ophthalmology-Oncology Collaboration

1/13/2021
Go online to PeerView.com/DMW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts, an oncologist and ophthalmologist, discuss the intricacies of ocular toxicities associated with multiple myeloma and explore the importance of collaborating when managing patients who are being treated with novel therapeutics. Upon completion of this activity, participants should be better able to: Identify ocular complications...

Duration:01:00:24

Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

1/11/2021
Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time,...

Duration:01:01:53

Thomas F. Patterson, MD, FACP, FIDSA - Overcoming Challenges in the Diagnosis and Treatment of Invasive Fungal Infections: A Visual Guide for Clinicians on the Front Lines of Patient Care

1/11/2021
Go online to PeerView.com/JZZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an infectious diseases specialist provides guidance on improving the diagnosis and treatment of invasive fungal infections. Upon completion of this activity, participants will be able to: Describe the epidemiology and risk factors for invasive fungal infections in patients who are immunocompromised and/or immunosuppressed, Promptly evaluate...

Duration:00:58:24

Steven Fishbane, MD / Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN - HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?

1/8/2021
Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia,...

Duration:01:19:17

Nathan H. Fowler, MD - Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL

1/8/2021
Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval...

Duration:01:25:11

Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath - Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

1/8/2021
Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this...

Duration:01:34:02

Sean Pokorney, MD, MBA - Improving Recognition of Nonvalvular Atrial Fibrillation to Reduce the Risk of Preventable Stroke: A Visual Guide for Clinicians

1/8/2021
Go online to PeerView.com/PFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, cardiologists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with or at risk for NVAF. Upon completion of this activity, participants should be better able to: Employ various evidence-based...

Duration:00:40:45

Javed Butler, MD, MPH, MBA - Making the Case for Treating Iron Deficiency in Patients With Heart Failure

1/8/2021
Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to:...

Duration:00:35:33

Bruce R. Korf, MD, PhD - Targeting the RAS/MAPK Pathway in Neurofibromatosis Type 1 and Plexiform Neurofibromas: Improving Patient Outcomes With an Innovative Therapeutic Approach

1/8/2021
Go online to PeerView.com/QAD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. Currently there is only one MEK...

Duration:01:30:47

Jarushka Naidoo, MB, BCH, MHS / Andrew Stolbach, MD, MPH - Emergency Department on Alert: Solving Oncologic Emergency Quandaries During the Immuno-Oncology Era and COVID-19 Pandemic

1/6/2021
Go online to PeerView.com/NDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts provides effective and practical guidance on strategies and techniques for triaging, diagnosing, monitoring, and managing patients who present to the emergency department with immune-related adverse events, as well as special considerations for optimizing the management of oncologic emergencies during the COVID-19 pandemic....

Duration:01:28:28

Robin L. Jones, MD/ Kristen Ganjoo, MD/ Emanuela Palmerini, MD, PhD - Solutions for Tenosynovial Giant Cell Tumors: Employing Effective Multimodal and Multidisciplinary Approaches to Patient Care

1/6/2021
Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity,...

Duration:00:56:39

Kathleen N. Moore, MD, MS / Kristi Jhangiani, PharmD, BCPS - Managed Care Implications of the Expanding Role of PARP Inhibitors in Oncology: Evolving Evidence Base, Current Value Assessment Frameworks, and Considerations for Decision-Making in Managed Car

1/4/2021
Go online to PeerView.com/QQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PARP inhibitors have transformed the treatment of multiple cancers in recent years. Indeed, many agents have yielded promising clinical data and received regulatory approval for a number of solid tumors, providing newer alternatives for cancer patients, especially those with limited therapeutic options. Key clinical aspects associated with maximizing the...

Duration:01:32:57

Naval Daver, MD / Harry P. Erba, MD, PhD / Tara Lin, MD / Gail J. Roboz, MD -How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

1/4/2021
Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts...

Duration:01:39:38

Amit Singal, MD, MS - Unraveling the Intricacies of HCC Management With Your Multidisciplinary Team: A Closer Look at Effective Selection and Sequencing Strategies in an Expanding Treatment Landscape

1/4/2021
Go online to PeerView.com/CWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of hepatocellular carcinoma (HCC) is in the midst of a therapeutic paradigm shift. Partial hepatectomy, liver transplantation, ablation, radiation therapy, and embolization procedures remain important interventions for localized HCC, whereas sorafenib, a multikinase inhibitor, was the cornerstone of therapy for patients with extrahepatic disease....

Duration:01:32:14

Margaret von Mehren, MD - Personalizing and Prolonging Care in GIST: Expert Guidance on Integrating New TKI Strategies

1/4/2021
Go online to PeerView.com/MER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Our understanding of the pathogenesis of GISTs was revolutionized by the discovery of KIT and PDGFRα mutations, which provided a diagnostic criteria and expanded treatment options. Tyrosine kinase inhibitors (TKIs), imatinib, sunitinib, and regorafenib...

Duration:00:58:19

Toni K. Choueiri, MD / David F. McDermott, MD / Nizar M. Tannir, MD, FACP - At the Therapeutic Crossroads for RCC: Investigating the Current Applications, Controversies, and Future Use of Immunotherapy and Targeted Agents

1/4/2021
Go online to PeerView.com/QRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel targeted, immune-based, and tyrosine kinase inhibitors (TKIs) to the treatment armamentarium. Most recently, these advances have included the validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus...

Duration:01:03:50

Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

12/30/2020
Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic...

Duration:01:04:27

David F. McDermott, MD - How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology

12/28/2020
Go online to PeerView.com/TKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With new developments in the advanced renal cell carcinoma (RCC) treatment landscape, clinicians have more opportunities for personalizing therapeutic approaches for patients with RCC. Validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents, have led to FDA approvals, and novel approaches...

Duration:01:02:11